Jinle Tang

Jinle Tang

Auto-generated profile, based on publicly available information

Jinle Tang

Shenzhen Bay Laboratory

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Cancer Cell
Verified
Journal Article
Closed access
XZXing-Ding Zhang
Xing-Ding Zhang
VBVeerabhadran Baladandayuthapani
Veerabhadran Baladandayuthapani
HLHeather Lin
Heather Lin
GMGeorge Mulligan
George Mulligan
BLBin Li
Bin Li
RORobert Zygmunt Orlowski
Robert Zygmunt Orlowski

12 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JTJinle Tang
Jinle Tang
JLJialu Li
Jialu Li
XZXuejun Zhu
Xuejun Zhu
YYYuan Yu
Yuan Yu
DCDan Chen
Dan Chen
LYLin Yang
Lin Yang
Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells

13 March 2015 in Cancer Science
Verified
Journal Article
Open access
JZJianxuan Zou
Jianxuan Zou
DCDan Chen
Dan Chen
YZYunhui Zong
Yunhui Zong
SYSisi Ye
Sisi Ye
JTJinle Tang
Jinle Tang
LYLin Yang
Lin Yang
Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab‐CD3), showed great performance in clinical treatment. We have successfully developed a single‐chain variable fragment (ScFv) combination of anti‐CD3 ScFv and anti‐CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T‐cell engager (BiTE) with an additional hIgFc (BiTE‐hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI‐8226 or U266). In addition, BiTE‐hIgFc (STL001) has nanomolar‐level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI‐8226 cells than that of separate aCD3‐ScFv‐hIgFc and aCD138‐ScFv‐hIgFc, or the isotype mAb in vitro or in vivo.

13 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LQLin Qi
Lin Qi
XSXue Sun
Xue Sun
FLFeng-E Li
Feng-E Li
BZBao-Song Zhu
Bao-Song Zhu
FBFrank K Braun
Frank K Braun
XZXing-Ding Zhang
Xing-Ding Zhang
Impairments in mitochondrial energy metabolism are thought to be involved in many neurodegenerative diseases. The mitochondrial inhibitor 3-nitropropionic acid (3-NP) induces striatal pathology mimicking neurodegeneration in vivo. Previous studies showed that 3-NP also triggered autophagy activation and apoptosis. In this study, we focused on the high-mobility group box 1 (HMGB1) protein, which is important in oxidative stress signaling as well as in autophagy and apoptosis, to explore whether the mechanisms of autophagy and apoptosis in neurodegenerative diseases are associated with metabolic impairment. To elucidate the role of HMGB1 in striatal degeneration, we investigated the impact of HMGB1 on autophagy activation and cell death induced by 3-NP. We intoxicated rat striata with 3-NP by stereotaxic injection and analyzed changes in expression HMGB1, proapoptotic proteins caspase-3 and phospho-c-Jun amino-terminal kinases (p-JNK). 3-NP–induced elevations in p-JNK, cleaved caspase-3, and autophagic marker LC3-II as well as reduction in SQSTM1 (p62), were significantly reduced by the HMGB1 inhibitor glycyrrhizin. Glycyrrhizin also significantly inhibited 3-NP–induced striatal damage. Neuronal death was replicated by exposing primary striatal neurons in culture to 3-NP. It was clear that HMGB1 was important for basal autophagy which was shown by rescue of cells through HMGB1 targeting shRNA approach.3-NP also induced the expression of HMGB1, p-JNK, and LC3-II in striatal neurons, and p-JNK expression was significantly reduced by shRNA knockdown of HMGB1, an effect that was reversed by exogenously increased expression of HMGB1. These results suggest that HMGB1 plays important roles in signaling for both autophagy and apoptosis in neurodegeneration induced by mitochondrial dysfunction.

21 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SDSalima Daou
Salima Daou
MTManisha Talukdar
Manisha Talukdar
JTJinle Tang
Jinle Tang
BDBeihua Dong
Beihua Dong
SBShuvojit Banerjee
Shuvojit Banerjee
FSFrank Sicheri
Frank Sicheri
Significance: The OAS–RNase L system is an innate immunity pathway activated by viral infection. Viral dsRNA stimulates OAS enzymes to produce short 2′,5′-oligoadenylates (2-5A) that activate RNase L, resulting in cleavage of single-stranded (ss) RNA. We discovered a small-molecule inhibitor of RNase L that rescues the toxic phenotype of cells deficient in the dsRNA-editing enzyme ADAR1. ADAR1 destabilizes dsRNA to prevent OAS activity. ADAR1 mutations are responsible for a subset of cases of Aicardi-Goutières syndrome (AGS), a severe neurodevelopmental and inflammatory genetic disease of children with no effective medical therapy. We posit that an RNase L inhibitor may have utility against cases of AGS in which RNase L is activated and other indications where overactivation of RNase L is harmful.

28 November 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JTJinle Tang
Jinle Tang
BDBeihua Dong
Beihua Dong
MLMing Liu
Ming Liu
SLShuyan Liu
Shuyan Liu
XNXiaogang Niu
Xiaogang Niu
HHHao Huang
Hao Huang